TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy.

Mol Cancer Ther · 2026 · PMC13044525 · PMID 41504346

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The total clearance was 4.2 to 11.8 mL/hour/kg, exhibiting a decreasing trend with increase in dose (Supplementary Fig.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.